GeneLink (OTCMKTS:GNLKQ) & Veracyte (NASDAQ:VCYT) Head to Head Survey

GeneLink (OTCMKTS:GNLKQ) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations.

Risk and Volatility

GeneLink has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for GeneLink and Veracyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GeneLink	0	0	0	0	0.00
Veracyte	1	1	7	0	2.67

Veracyte has a consensus price target of $41.13, indicating a potential upside of 3.85%. Given Veracyte’s stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than GeneLink.

Earnings and Valuation

This table compares GeneLink and Veracyte”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GeneLink	N/A	N/A	N/A	N/A	N/A
Veracyte	$425.33 million	7.22	-$74.40 million	($0.15)	-264.00

GeneLink has higher earnings, but lower revenue than Veracyte.

Profitability

This table compares GeneLink and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GeneLink	N/A	N/A	N/A
Veracyte	-2.18%	3.02%	2.80%

Summary

Veracyte beats GeneLink on 7 of the 8 factors compared between the two stocks.

About GeneLink

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.